Nash Videos

▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.

Clinical Chemistry in NAFLD Part 2 – Biomarkers and Hepatic Steatosis and NASH

Clinical Chemistry in NAFLD Part 2 – Biomarkers, Hepatic Steatosis and NASH

Discover how key biomarkers like Fatty Liver Index and SteatoTest are transforming NAFLD diagnosis and management. Delve into the disease's pathophysiology, the impact of obesity and insulin resistance, and the advancements in specialized liver tests.
View More ⏩Clinical Chemistry in NAFLD Part 2 – Biomarkers, Hepatic Steatosis and NASH

Clinical Chemistry in NAFLD Part 1 – Interest and Why?

Explore the complexities of NAFLD (Non-Alcoholic Fatty Liver Disease), now also known as MAFLD, and its evolving terminology, diagnostic challenges, and association with cardio-metabolic syndrome. Learn about its progressive nature, the gold standard for diagnosis, and the emerging role of biomarkers. A must-read for healthcare professionals aiming for early diagnosis and effective management.
View More ⏩Clinical Chemistry in NAFLD Part 1 – Interest and Why?
NAFLD Pathophysiologic Role of Intrahepatic Vasculature

NAFLD Pathophysiologic Role of Intrahepatic Vasculature

Dr. Kwanten (Belgium) discusses the pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease (NAFLD). He mentions that portal hypertension is present in patients with NAFLD and can be evident in the early stages which is caused by intrahepatic vascular alterations. Further, he explores the different types of drugs that will help change the course of the disease.
View More ⏩NAFLD Pathophysiologic Role of Intrahepatic Vasculature
Dr. Vlad Ratziu - France

Fibrosis vs. steatohepatitis in NASH: key prognostic and regulatory implications

Fibrosis is an independent predictor of liver-related mortality but rarely if ever occurs without NASH as NASH is the progressive form of the disease and drives fibrosis progression. This means the question arises on whether anti-fibrotic drugs are better than anti-NASH drugs and vice versa which Dr. Vlad Ratziu explores in this video.
View More ⏩Fibrosis vs. steatohepatitis in NASH: key prognostic and regulatory implications

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES